Elshafeey Abdallah
Department of Medicine, Johns Hopkins Hospital, Baltimore, MD 21287, USA.
J Cardiovasc Dev Dis. 2025 May 20;12(5):196. doi: 10.3390/jcdd12050196.
Cardiovascular disease (CVD) is one of the largest global disease burdens. Despite guidelines and recommendations and the proven advantages of lipid-lowering therapies (LLTs) in preventing CVD, achieving treatment targets remains disappointing. A key barrier to optimal LLT is therapy discontinuation. To be widely adopted in clinical practice, new lipid-lowering therapies must both prevent major adverse cardiovascular events (MACEs) and exhibit cost effectiveness to ensure widespread utilization by patients, physicians, and insurers. While non-statin LLTs have shown cardiovascular value, their cost effectiveness is controversial. This review highlights the LLTs that are currently widely adopted and summarizes the available evidence on their cost effectiveness.
心血管疾病（CVD）是全球最大的疾病负担之一。尽管有指南和建议，且降脂疗法（LLTs）在预防心血管疾病方面已被证实具有优势，但实现治疗目标的情况仍然令人失望。最佳降脂疗法的一个关键障碍是治疗中断。要在临床实践中广泛应用，新的降脂疗法必须既能预防主要不良心血管事件（MACEs），又能展现成本效益，以确保患者、医生和保险公司广泛使用。虽然非他汀类降脂疗法已显示出心血管方面的价值，但其成本效益存在争议。本综述重点介绍了目前广泛采用的降脂疗法，并总结了其成本效益的现有证据。
